Laurens Liesenborghs to Bradykinin
This is a "connection" page, showing publications Laurens Liesenborghs has written about Bradykinin.
Connection Strength
0.046
-
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020 Dec 09; 21(1):1005.
Score: 0.046